Working… Menu
Trial record 100 of 264 for:    Estrogen Resistance

Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00084396
Recruitment Status : Completed
First Posted : June 11, 2004
Last Update Posted : September 26, 2016
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. Giving letrozole before surgery may shrink the tumor so that it can be removed.

PURPOSE: This phase II trial is studying how well neoadjuvant letrozole works in treating postmenopausal women who are undergoing surgery for estrogen-receptor positive or progesterone-receptor positive stage II, stage IIIA, or stage IIIB breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: letrozole Procedure: conventional surgery Phase 2

Detailed Description:



  • Develop a predictive model of response (based on gene expression profiling) in postmenopausal women with estrogen- and/or progesterone-receptor positive stage II, IIIA, or IIIB breast cancer treated with neoadjuvant letrozole.


  • Determine the response rate in patients treated with this drug.
  • Determine changes in Ki67 proliferation rates in patients treated with this drug.
  • Determine the rate of improvement in surgical outcomes in patients treated with this drug.
  • Determine the long-term outcomes in patients treated with this drug.
  • Determine the safety of this drug in these patients.
  • Determine mechanisms of resistance to this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive neoadjuvant oral letrozole once daily for 16 weeks in the absence of disease progression. Patients then undergo breast surgery one day after the last dose of letrozole. Patients with partial response after 16 weeks may continue to receive letrozole for an additional 8 weeks before undergoing breast surgery.

Patients are followed within 4 weeks after definitive surgery and then annually for 10 years.

PROJECTED ACCRUAL: A total of 150 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 115 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Trial Of 4 Months Preoperative Letrozole 2.5 mg Daily For Postmenopausal Women With Estrogen Receptor Positive And/Or Progesterone Receptor Positive T2, T3, T4a-c, N0-2, M0 Breast Cancer- Novel Biomarkers for Aromatase Inhibitor Therapy
Study Start Date : October 2003
Actual Primary Completion Date : March 2007
Actual Study Completion Date : September 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Letrozole/Surgery Drug: letrozole
Procedure: conventional surgery

Primary Outcome Measures :
  1. Predictive model for response as assessed by gene expression profiling

Secondary Outcome Measures :
  1. Response rate
  2. Changes in Ki67 proliferation rates
  3. Rate of improvement in surgical outcomes
  4. Long-term outcomes
  5. Safety
  6. Mechanisms of resistance

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically confirmed infiltrating adenocarcinoma of the breast by core needle biopsy

    • Clinical stage T2-T4a-c, N0-2, M0
  • Palpable and measurable disease
  • Previously untreated disease
  • Benefits from neoadjuvant therapy that would improve surgical outcome AND meets criteria for 1 of the following:

    • Marginal candidate for lumpectomy (e.g., lumpectomy feasible but patient at risk for positive margins or poor cosmetic outcome) AND patient desires breast-conserving surgery
    • Ineligible for lumpectomy due to size of primary tumor, but modified radical mastectomy feasible AND patient desires breast-conserving surgery
    • Inoperable disease AND systemic therapy required for disease to become operable by modified radical mastectomy
  • Bilateral primary tumors allowed provided both tumors are consistent with entry criteria
  • No inflammatory carcinoma (defined as peau d' orange affecting at least one third of the breast)

    • Direct extension of the tumor to the skin allowed
  • No metastatic breast disease, except isolated ipsilateral supraclavicular lymphadenopathy
  • Hormone receptor status:

    • Estrogen- and/or progesterone-receptor positive disease based on 10% or more nuclear staining of the invasive component of the tumor



  • Postmenopausal


  • Female

Menopausal status

  • Postmenopausal, defined as meeting 1 of the following criteria:

    • Cessation of menstrual periods for at least 1 year
    • Bilateral surgical oophorectomy
    • Follicle-stimulating hormone and estradiol levels in the postmenopausal range

Performance status

  • ECOG 0-2

Life expectancy

  • Not specified


  • Not specified


  • No severe liver dysfunction that would preclude study participation


  • Not specified


  • Willing and able to provide biopsy material
  • Willing to undergo breast surgery after neoadjuvant treatment
  • No condition (e.g., confusion, infirmity, or alcoholism) that would preclude study compliance
  • No other concurrent active and progressive invasive malignancies
  • No other concurrent severe disease that would preclude study participation


Biologic therapy

  • No concurrent immunotherapy or biological response modifiers for breast cancer


  • No prior chemotherapy for breast cancer
  • No concurrent chemotherapy for breast cancer

Endocrine therapy

  • At least 2 weeks since prior hormone replacement therapy or phytoestrogenic herbal, alternative, or over-the-counter (OTC) sex hormone remedies
  • No prior hormonal agents for breast cancer
  • No prior aromatase inhibitors, tamoxifen, raloxifene, or other antiestrogen or selective estrogen receptor modulators
  • No concurrent drugs known to affect sex hormone status, including hormone replacement therapy or phytoestrogenic herbal, alternative, or OTC remedies
  • No other concurrent endocrine therapy for breast cancer


  • No prior radiotherapy for breast cancer
  • No concurrent radiotherapy for breast cancer


  • Prior sentinel node biopsy allowed
  • No other concurrent surgery for breast cancer


  • More than 30 days since prior non-approved or experimental drugs
  • Concurrent bisphosphonates for osteoporosis allowed
  • No other concurrent treatment for breast cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00084396

Layout table for location information
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
Sponsors and Collaborators
Washington University School of Medicine
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Michael Naughton, M.D. Washington University School of Medicine

Layout table for additonal information
Responsible Party: Washington University School of Medicine Identifier: NCT00084396     History of Changes
Other Study ID Numbers: CDR0000361963
R01CA095614 ( U.S. NIH Grant/Contract )
P30CA091842 ( U.S. NIH Grant/Contract )
First Posted: June 11, 2004    Key Record Dates
Last Update Posted: September 26, 2016
Last Verified: September 2016
Keywords provided by Washington University School of Medicine:
stage II breast cancer
stage IIIA breast cancer
stage IIIB breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Estrogen Antagonists
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hormone Antagonists